Abstract: The present invention provides an aptamer that binds to chymase, and contains a common sequence represented by UAACR1N1R2GGGG wherein R1 and R2 are each any one base, and N1 shows 3 to 30 bases (uracil is optionally thymine).

Abstract: The present invention provides an aptamer that binds to chymase, and contains a common sequence represented by UAACR1N1R2GGGG wherein R1 and R2 are each any one base, and N1 shows 3 to 30 bases (uracil is optionally thymine).

Abstract: An effective therapeutic agent for subretinal hyperreflective material or retinal diseases accompanying subretinal hyperreflective material is provided by the present invention. Specifically, a therapeutic agent for subretinal hyperreflective material or a retinal disease accompanying subretinal hyperreflective material, containing an aptamer that binds to FGF2 or a salt thereof is provided.

Abstract: The present invention provides an aptamer containing a sequence shown by the following formula (1) or formula (2): (1) GGGGCCUCC-N1-GGACYAAACC (2) GGGGCCUCC-N1-GGACWYAAACC wherein N1 shows 3 to 24 bases in length, Y is C or U, and W is A or U (uracil is optionally thymine), wherein the aptamer binds to a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS5).

Abstract: The present invention aims to provide an aptamer for TGF-?1. An aptamer having four sets of consecutive G bases, and a combination of the nucleotide sequences represented by the following formula (I) and the formula (II) which binds to TGF-?1 may be useful as a medicament for preventing and/or treating various diseases involving activation of TGF-?1, or a diagnostic agent, or a labeling agent: UAAX??formula (I): ARACUU??formula (II): wherein X is a bond or GU; and R is A or G.

Abstract: The present invention provides a preparation formulation capable of stably maintaining the activity of an aptamer, particularly an aptamer for FGF2, for a long term, thereby providing a pharmaceutical preparation containing an aptamer, particularly an FGF2 aptamer, as an active ingredient.

Abstract: The present invention provides an aptamer containing a sequence shown by the following formula (1) or formula (2): (1) GGGGCCUCC-N1-GGACYAAACC (2) GGGGCCUCC-N1-GGACWYAAACC wherein N1 shows 3 to 24 bases in length, Y is C or U, and W is A or U (uracil is optionally thymine), wherein the aptamer binds to a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS5).

Abstract: The present invention provides an aptamer that binds to chymase, and contains a common sequence represented by UAACR1N1R2GGGG wherein R1 and R2 are each any one base, and N1 shows 3 to 30 bases (uracil is optionally thymine).

Abstract: Provided are an aptamer having an inhibitory activity against NGF; a complex containing an aptamer having a binding activity or inhibitory activity against NGF and a functional substance (e.g., affinity substances, labeling substances, enzymes, drug delivery vehicles, drugs and the like); a medicament, a diagnostic agent, a labeling agent and the like containing an aptamer having a binding activity or inhibitory activity against NGF, or a complex containing the aptamer and the functional substance; and the like.

Abstract: Provided by the present invention are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or labeling agent containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: Provided by the present invention are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or labeling agent containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: The present invention provides an aptamer that binds to an autotaxin, which contains a nucleotide sequence represented by the following formula (I): CGGAACC-N1-GGTC??(I) wherein N1 shows any of 3 to 11 nucleotides, and a utilization method thereof.

Abstract: The present invention provides an aptamer binding to an autotaxin, which contains a nucleotide sequence represented by the formula: (SEQ ID NO: 42) GWAACAGGUUUUGCU wherein W is A or U (provided uracil is optionally thymine), and which is the following (a) or (b): (a) an aptamer wherein, in the nucleotides contained in the aptamer, (i) the 2?-position of the ribose of each pyrimidine nucleotide is a fluorine atom, (ii) the 2?-position of the ribose of each purine nucleotide is a hydroxy group; (b) the aptamer of (a), wherein (i) the fluorine atom at the 2?-position of the ribose of each pyrimidine nucleotide is independently unsubstituted, or substituted by an atom or group selected from the group consisting of a hydrogen atom, a hydroxy group and a methoxy group, (ii) the hydroxy group at the 2?-position of the ribose of each purine nucleotide is independently unsubstituted, or substituted by an atom or group selected from the group consisting of a hydrogen atom, a methoxy group a

Abstract: The present invention provides an aptamer binding to NGF and capable of forming a potential secondary structure represented by the formula (I): wherein N is one nucleotide selected from the group consisting of A, G, C, U and T, N11-N13, N21-N23, N32-N38 and N42-N48 are the same or different and each is a bond or 1 or 2 nucleotides selected from the group consisting of A, G, C, U and T, N14, N24, N31, N41, N39 and N49 are the same or different and each is one nucleotide selected from the group consisting of A, G, C, U and T, N14 and N24, N31 and N41, and N39 and N49 each form a Watson-Crick base pair, N11-N12-N13-N14 and N21-N22-N23-N24 are nucleotide sequences capable of forming a stem structure in combination, and N31-N32-N33-N34-N35-N36-N37-N38-N39 and N41-N42-N43-N44-N45-N46-N47-N48-N49 are nucleotide sequences capable of forming a stem structure in combination.

Abstract: The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I): wherein X1, X2, X5 and X6 are the same or different and each is one or two nucleotides selected from the group consisting of A, G, C, U and T, or a bond, X1 and X6, and X2 and X5 each form a Watson-Crick base pairs, and X3 and X4 are the same or different and each is a nucleotide selected from A, G, C, U and T.

Abstract: Provided is a higher quality aptamer having a binding activity to NGF. An aptamer binding to NGF, which satisfies the following (1) and (2): (1) containing the sequence represented by UGAAARAAACC (SEQ ID NO: 64) or CGAAMRAAACU (SEQ ID NO: 65), and (2) having a base length of not more than 73.

Abstract: Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by X1GAUAGAN1N2UAAX2 wherein X1 and X2 are the same or different and each is A or G, and N1 and N2 are the same or different and each is A, G, C, U or T; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a pharmaceutical or a reagent containing the aptamer or complex; a detection and a purification methods of chymase using the aptamer or complex and the like.

Abstract: Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Abstract: The present invention provides a novel aptamer for IgG and a method for utilizing the same and the like. More specifically, the present invention provides an aptamer that binds to an Fc region of IgG (e.g., human IgG); a complex comprising an aptamer and a functional substance bound thereto (e.g., affinity substance, labeling substance, enzyme, drug, toxin, drug delivery vehicle); a solid phase carrier with an aptamer or complex immobilized thereon; medical equipment comprising a solid phase carrier; a method for antibody purification comprising adsorbing an IgG antibody to a solid phase carrier, and eluting the adsorbed IgG antibody with an eluent; a method for producing a purified antibody, comprising preparing an IgG antibody and purifying the prepared IgG antibody with a solid phase carrier and the like.